Abstract Massive sequencing platforms allow the identification of complex clinical phenotypes involving more than one autosomal recessive disorder. In this study, we report on an adult patient, born to a related couple (third degree cousins), referred for genetic evaluation due to ectopia lentis, deafness and previous diagnosis of juvenile idiopathic arthritis. He was biochemically diagnosed as having Classic Homocystinuria (HCU); Sanger sequencing of the CBS gene showed the genotype NM_000071.2(CBS):c.[833T>C];[833T>C], compatible with the diagnosis of pyridoxine-responsive HCU. As he also had symptoms not usually associated with HCU, exome sequencing was performed. In addition to the variants found in the Sanger sequencing, the following variants were identified: NM_001256317.1(TMPRSS3):c.[413C>A];[413C>A]; and the NM_005807.6(PRG4):c.[3756dup]:[3756dup], confirming the diagnosis of autosomal recessive nonsyndromic deafness and Camptodactyly-Arthropathy-Coxa Vara-Pericarditis Syndrome (CACP), respectively. Genomic analysis allowed the refinement of the diagnosis of a complex case and improvement of the patient’s treatment. disorder study patient third cousins, cousins , cousins) lentis arthritis HCU (HCU) NM_000071.2CBSc.833T>C833T>C, NM0000712CBSc833TC833TC NMCBScTCTC NM_000071.2 c. 833T>C NM 000071 2 c 833T C T NM_000071.2(CBS):c.[833T>C];[833T>C] pyridoxineresponsive pyridoxine responsive performed identified NM_001256317.1TMPRSS3c.413C>A413C>A NM0012563171TMPRSS3c413CA413CA NMTMPRSScCACA NM_001256317.1 TMPRSS3 413C>A 001256317 1 413C A TMPRSS NM_001256317.1(TMPRSS3):c.[413C>A];[413C>A] NM_005807.6PRG4c.3756dup3756dup, NM0058076PRG4c3756dup3756dup NMPRGcdupdup NM_005807.6 PRG4 3756dup 005807 6 PRG dup NM_005807.6(PRG4):c.[3756dup]:[3756dup] CamptodactylyArthropathyCoxa Camptodactyly Arthropathy Coxa VaraPericarditis Vara Pericarditis CACP, CACP (CACP) respectively patients s treatment (HCU 2CBSc C833T CBSc NM_000071.2CBSc.833T>C833T>C TC NM0000712 NM_000071. 833TC 00007 NM_000071.2(CBS):c.[833T>C];[833T>C 1TMPRSS3c A413C CA NM0012563171 NM_001256317. 413CA 00125631 NM_001256317.1(TMPRSS3):c.[413C>A];[413C>A 6PRG4c 3756dup3756dup NM_005807.6PRG4c.3756dup3756dup NM0058076 NM_005807. 00580 NM_005807.6(PRG4):c.[3756dup]:[3756dup (CACP CT NM000071 NM_000071 0000 TMPRSSc AC NM001256317 NM_001256317 0012563 PRGc dupdup NM005807 NM_005807 0058 NM00007 NM_00007 000 NM00125631 NM_00125631 001256 NM00580 NM_00580 005 NM0000 NM_0000 00 NM0012563 NM_0012563 00125 NM0058 NM_0058 NM000 NM_000 0 NM001256 NM_001256 0012 NM005 NM_005 NM00 NM_00 NM00125 NM_00125 001 NM0 NM_0 NM0012 NM_0012 NM_ NM001 NM_001

Resumo Antecedentes As lipofuscinoses ceroides neuronais (neuronal ceroid lipofuscinoses, NCLs, em inglês) são um grupo de doenças autossômicas recessivas, hereditárias, lisossomais e neurodegenerativas que causam demência progressiva, crises epiléticas, distúrbios de movimento, atraso/regressão da linguagem, deficiência visual progressiva e morte precoce. A lipofuscinose ceroide neuronal tipo 2 (neuronal ceroid lipofuscinosis type 2, CLN2, em inglês), causada por variantes patogênicas bialélicas do gene TPP1, é a única com terapia-alvo aprovada. O diagnóstico laboratorial é realizado por testes específicos, o que leva a atrasos diagnósticos e, consequentemente, prejudica a disponibilização de tratamento. A epilepsia é uma característica comum e clinicamente identificável entre as NCLs, e o início das convulsões é o principal motivo para as famílias buscarem atendimento médico. Objetivo Avaliar os resultados do Programa de Epilepsia e Genética da América Latina, um painel genético, como uma ferramenta abrangente para a investigação de CLN2 entre outras causas genéticas de epilepsia. Métodos Um total de 1.284 pacientes com epilepsia sem uma causa específica e que tinham pelo menos 1 sintoma associado à CLN2 foram rastreados em busca de variantes em 160 genes associados à epilepsia ou a distúrbios metabólicos que apresentam epilepsia, por meio de um painel genético. Resultados Variantes do gene TPP1 foram identificadas em 25 indivíduos (1,9%), sendo que ; 21 apresentavam duas variantes. As duas variantes mais frequentes foram p.Arg208* e p.Asp276Val, e duas variantes novas foram detectadas neste: p.Leu308Pro e c.89 + 3G > C Intron 2. Conclusão Os resultados sugerem que os painéis genéticos de epilepsia podem ser uma ferramenta útil para confirmar ou excluir o diagnóstico de CLN2 e, se confirmado, fornecer tratamento específico para os pacientes. NCLs inglês recessivas hereditárias epiléticas movimento atrasoregressão atraso regressão linguagem precoce CLN inglês, , TPP terapiaalvo terapia alvo aprovada específicos consequentemente médico Latina genético 1284 284 1.28 16 1,9%, 19 1,9% 9 (1,9%) pArg208 pArg p Arg208 Arg p.Arg208 pAsp276Val pAspVal Asp276Val Asp Val p.Asp276Val neste pLeu308Pro pLeuPro Leu308Pro Leu Pro c89 c 89 c.8 G confirmado 128 28 1.2 1,9 (1,9% pArg20 Arg20 p.Arg20 pAsp AspVal pLeu LeuPro c8 8 c. 12 1. 1, (1,9 pArg2 Arg2 p.Arg2 (1, p.Arg (1 (

Abstract Background Neuronal ceroid lipofuscinoses (NCL) are a group of autosomal recessive, inherited, lysosomal, and neurodegenerative diseases that causes progressive dementia, seizures, movement disorders, language delay/regression, progressive visual failure, and early death. Neuronal ceroid lipofuscinosis type 2 (CLN2), caused by biallelic pathogenic variants of the TPP1 gene, is the only NCL with an approved targeted therapy. The laboratory diagnosis of CLN2 is established through highly specific tests, leading to diagnostic delays and eventually hampering the provision of specific treatment for patients with CLN2. Epilepsy is a common and clinically-identifiable feature among NCLs, and seizure onset is the main driver for families to seek medical care. Objective To evaluate the results of the Latin America Epilepsy and Genetics Program, an epilepsy gene panel, as a comprehensive tool for the investigation of CLN2 among other genetic causes of epilepsy. Methods A total of 1,284 patients with epilepsy without a specific cause who had at least 1 symptom associated with CLN2 were screened for variants in 160 genes associated with epilepsy or metabolic disorders presenting with epilepsy through an epilepsy gene panel. Results Variants of the TPP1 gene were identified in 25 individuals (1.9%), 21 of them with 2 variants. The 2 most frequently reported variants were p.Arg208* and p.Asp276Val, and 2 novel variants were detected in the present study: p.Leu308Pro and c.89 + 3G > C Intron 2. Conclusion The results suggest that these genetic panels can be very useful tools to confirm or exclude CLN2 diagnosis and, if confirmed, provide disease-specific treatment for the patients. (NCL recessive inherited lysosomal dementia seizures delayregression delay regression delay/regression failure death CLN2, CLN , (CLN2) TPP therapy tests clinicallyidentifiable clinically identifiable NCLs care Program panel 1284 284 1,28 16 1.9%, 19 1.9% 9 (1.9%) pArg208 pArg p Arg208 Arg p.Arg208 pAsp276Val pAspVal Asp276Val Asp Val p.Asp276Val study pLeu308Pro pLeuPro Leu308Pro Leu Pro c89 c 89 c.8 G confirmed diseasespecific disease (CLN2 128 28 1,2 1.9 (1.9% pArg20 Arg20 p.Arg20 pAsp AspVal pLeu LeuPro c8 8 c. (CLN 12 1, 1. (1.9 pArg2 Arg2 p.Arg2 (1. p.Arg (1 (

Resumo Lipofuscinose ceróide neuronal (CLN2) é uma doença genética neurodegenerativa rara que afeta crianças nos primeiros anos de vida. A sua forma clássica é rapidamente progressiva, levando à morte nos primeiros 10 anos. A necessidade de um diagnóstico precoce aumenta com a disponibilidade do tratamento de terapia enzimática. Um painel de nove neurologistas infantis brasileiros combinou sua experiência em CLN2 com evidências da literatura médica para estabelecer um consenso no manejo desta doença no Brasil. Eles votaram 92 questões abordando diagnóstico, manifestações clínicas e tratamento, considerando o acesso à saúde no Brasil. Deve-se suspeitar de CLN2 em qualquer criança de 2 a 4 anos de idade que apresente atraso de linguagem e epilepsia. Apesar da forma clássica ser a mais prevalente, podem ser encontrados casos atípicos com diferentes fenótipos. Eletroencefalograma, ressonância magnética, testes moleculares e bioquímicos são as principais ferramentas para investigar e confirmar o diagnóstico. No entanto, o acesso aos testes moleculares é limitado no Brasil, necessitando contar com o apoio da indústria farmacêutica. O manejo da CLN2 deve envolver uma equipe multidisciplinar e focar na qualidade de vida dos pacientes e no apoio familiar. A terapia de reposição enzimática com Cerliponase alfa é um tratamento inovador aprovado no Brasil desde 2018; ele retarda o declínio funcional e proporciona qualidade de vida. Diante das dificuldades para o diagnóstico e tratamento de doenças raras em nosso sistema público de saúde, o diagnóstico precoce de CLN2 precisa de melhorias pois a terapia de reposição enzimática está disponível e modifica o prognóstico dos pacientes. CLN (CLN2 progressiva 1 9 Devese Deve se epilepsia prevalente fenótipos Eletroencefalograma magnética entanto farmacêutica familiar 2018 (CLN 201 20

Abstract Neuronal ceroid lipofuscinosis type 2 (CLN2) is a rare neurodegenerative genetic disease that affects children in early life. Its classic form is rapidly progressive, leading to death within the first 10 years. The urge for earlier diagnosis increases with the availability of enzyme replacement therapy. A panel of nine Brazilian child neurologists combined their expertise in CLN2 with evidence from the medical literature to establish a consensus to manage this disease in Brazil. They voted 92 questions including diagnosis, clinical manifestations, and treatment of the disease, considering the access to healthcare in this country. Clinicians should suspect CLN2 disease in any child, from 2 to 4 years old, with language delay and epilepsy. Even though the classic form is the most prevalent, atypical cases with different phenotypes can be found. Electroencephalogram, magnetic resonance imaging, molecular and biochemical testing are the main tools to investigateand confirm the diagnosis. However, we have limited access to molecular testing in Brazil, and rely on the support from the pharmaceutical industry. The management of CLN2 should involve a multidisciplinary team and focus on the quality of life of patients and on family support. Enzyme replacement therapy with Cerliponase α is an innovative treatment approved in Brazil since 2018; it delays functional decline and provides quality of life. Given the difficulties for the diagnosis and treatment of rare diseases in our public health system, the early diagnosis of CLN2 needs improvement as enzyme replacement therapy is available and modifies the prognosis of patients. CLN (CLN2 progressive 1 9 manifestations country old epilepsy prevalent found Electroencephalogram imaging However industry 2018 system (CLN 201 20

Abstract Fructose-1,6-bisphosphatase (FBPase) deficiency is a rare inborn error of fructose metabolism caused by pathogenic variants in the FBP1 gene. As gluconeogenesis is affected, catabolic episodes can induce ketotic hypoglycemia in patients. FBP1 analysis is the most commonly used approach for the diagnosis of this disorder. Herein, a Brazilian patient is reported. The proband, a girl born to a consanguineous couple, presented with severe hypoglycemia crisis in the neonatal period. At the age 17 months, presented a new crisis accompanied by metabolic acidosis associated with a feverish episode. Genetic analysis was performed by next-generation sequencing (NGS), identifying the NM_000507.3:c.611_614del variant in homozygosis in the FBP1 gene. In silico analysis and 3D modeling were performed, suggesting that this variant is associated with a loss of sites for substrate and Mg2+ binding and for posttranslational modifications of FBPase. The c.611_614del variant is located in a repetitive region of the FBP1 gene that appears to be a hotspot for mutational events. This frameshift creates a premature termination codon in the last coding exon which escapes the nonsense-mediated decay mechanism, according to in silico analysis. This variant results in an intrinsically disordered protein with loss of substrate recognition and post-translational modification sites.

RESUMO A doença de Gerstmann-Sträussler-Scheinker é uma doença priônica genética, cuja mutação mais frequente é p.Pro102Leu. Descrevem-se dados clínicos, moleculares e neuropatológicos de sete indivíduos em duas famílias não relacionadas com p.Pro102Leu. Diferenças notáveis entre os pacientes em relação à idade de início, duração da doença e apresentação clínica foram encontradas. Na primeira família, dois pacientes apresentaram demência rapidamente progressiva e três apresentaram fenótipo de ataxia com idade variáveis de início e duração da doença. Nesta família, a idade de início entre mãe e filha diferiu em 39 anos. Na segunda família, fenótipos diferentes foram observados e idades precoces de início dos sintomas foram associadas à heterozigose no códon 129. Não houve diferença em relação ao genótipo do gene da apoE. O genótipo do códon 129 não foi responsável pela variabilidade clínica; heterozigose no códon 129 esteve associada ao início precoce da doença. O exame neuropatológico em dois pacientes confirmou presença de placas típicas e imunohistoquímica para PrPsc.

ABSTRACT Gerstmann-Sträussler-Scheinker is a genetic prion disease and the most common mutation is p.Pro102Leu. We report clinical, molecular and neuropathological data of seven individuals, belonging to two unrelated Brazilian kindreds, carrying the p.Pro102Leu. Marked differences among patients were observed regarding age at onset, disease duration and clinical presentation. In the first kindred, two patients had rapidly progressive dementia and three exhibited predominantly ataxic phenotypes with variable ages of onset and disease duration. In this family, age at disease onset in the mother and daughter differed by 39 years. In the second kindred, different phenotypes were also reported and earlier ages of onset were associated with 129 heterozygosis. No differences were associated with apoE genotype. In these kindreds, the codon 129 polymorphism could not explain the clinical variability and 129 heterozygosis was associated with earlier disease onset. Neuropathological examination in two patients confirmed the presence of typical plaques and PrPsc immunopositivity.

RESUMO OBJETIVO: Determinar a prevalência de mutações no DNA mitocondrial (DNAmt) em casos com achados compatíveis com o diagnóstico de síndrome de Leigh em um Servicro de Neurologia brasileiro, e comparar essas descobertas entre os pacientes que apresentam ou não essas mutações. MÉTODO: Seis pontos de mutações do DNAmt (T8993G, T8993C, T8851C, G1644T, T9176C e T3308C) foram analisados por PCR e digestão com endonuclease em 32 pacientes com diagnóstico presuntivo de síndrome de Leigh, de acordo com a distribuição em diferentes faixas etárias. RESULTADOS: Dois pacientes no subgrupo abaixo de 4 anos de idade apresentaram as mutações T8993G e T8993C do DNAmt. Os sintomas clínicos e os achados de neuroimagens destes dois pacientes foram similares aos dos casos sem mutações detectadas. CONCLUSÃO: Como a confirmaçãoo molecular é fundamental tanto para o aconselhamento genético como para a orientação terapêutica, enfatizamos o benefício da pesquisa de mutações no DNAmt em pacientes com fenótipo de Síndrome de Liegh abaixo de 4 anos de idade. O sequenciamento em larga escala do genoma mitocondrial e do exoma completo por tecnologia de sequenciamento de nova geração poderá ser uma alternativa futura no estabelecimento do diagnóstico molecular nesta síndrome genética extensamente heterogênea.

OBJECTIVE: To determine the prevalence of mitochondrial DNA (mtDNA) mutations in cases with findings compatible with the diagnosis of Leigh syndrome in a Brazilian Neurological Service, and to compare those findings between the patients presenting or not these mutations. METHOD: We analyzed six mtDNA point mutations (T8993G, T8993C, T8851C, G1644T, T9176C, and T3308C) by PCR and endonuclease digestion in 32 patients with presumptive diagnosis of Leigh syndrome, according to distribution across different age ranges. RESULTS: We found two patients, in the subgroup under 4 years of age, presenting T8993G and T8993C mutations. Their clinical symptoms and neuroimaging findings were similar when compared to those patients not harboring these mutations. CONCLUSION: As the molecular confirmation is pivotal for both the precise genetic counselling and therapeutic guidance, we emphasise the benefit of screening for mtDNA mutation in Leigh syndrome patients under 4 years old. Mitochondrial whole genome and whole exome analysis by next-generation sequencing technology maybe a future alternative for molecular diagnosis of this extensive genetic heterogeneous syndrome.

Leucodistrofias são doenças geneticamente determinadas. Apesar das leucodistrofias afetarem principalmente crianças lactentes e infantes, estas doenças podem acometer a faixa etária adulta. Nos adultos, as leucodistrofias podem ter uma apresentação clínica e de imagem distinta daquela da infância. Um aumento na suspeita clínica de leucodistrofias com início tardio deve ocorrer associado ao aparecimento de novas alternativas terapêuticas. Este artigo de revisão descreve sumariamente as características de imagem nas leucodistrofias no adulto.

Leukodystrophies are genetically determined white matter disorders. Even though leukodystrophies essentially affect children in early infancy and childhood, these disorders may affect adults. In adults, leukodystrophies may present a distinct clinical and imaging presentation other than those found in childhood. Clinical awareness of late-onset leukodystrophies should be increased as new therapies emerge. MRI is a useful tool to evaluate white matter disorders and some characteristics findings can help the diagnosis of leukodystrophies. This review article briefly describes the imaging characteristics of the most common adult leukodystrophies.

As populações do nordeste brasileiro possuem elevadas taxas de endogamia e deficiências. Neste trabalho, foi realizado um estudo epidemiológico transversal com método do informante para descrever doenças genéticas e as adquiridas que causam deficiências físicas em oito municípios da Paraíba e estimar os custos por serviços especializados de fisioterapia e aquisição de equipamentos de tecnologia assistiva. De uma população de 48.499 habitantes, 338 pessoas foram triadas e 123 (0,34%) realizaram avaliação clínico-genética e funcional por uma equipe multidisciplinar de especialistas. Fatores genéticos foram responsáveis por 58,5% das deficiências, sendo encontrados alguns agrupamentos de afecções prevalentes nas populações amostradas: amiotrofia espinal progressiva, ataxia espinocerebelar, distrofia muscular e síndrome Spoan. A descrição do perfil socioeconômico e das demandas por serviços de reabilitação e tecnologia assistiva apontam para necessidade de estabelecimento de políticas públicas específicas para essas comunidades.

The population of the northeast of Brazil is characterized by high rates of endogamy and disabilities. An epidemiological cross-sectional study using the informant method was conducted in eight communities in the hinterlands of Paraiba to describe genetic and acquired diseases that cause disabilities and to estimate the costs of specialized services such as physiotherapy and the acquisition of technological assistential equipment. From a population of 48,499 inhabitants, 338 individuals were screened and 123 (0.34%) were clinically, genetically and functionally assessed by a multidisciplinary team of specialists. Genetic factors were responsible for 58.5% of the disabilities, with some clusters of prevalent diseases being found within the sampled communities, namely progressive spinal muscular atrophy, spinocerebellar ataxia, muscular dystrophy and Spoan syndrome. The socioeconomic profile and the demand for rehabilitation services and technological assistance highlight the need to introduce and implement specific public health policies in these communities.

As populações do nordeste brasileiro possuem elevadas taxas de endogamia e deficiências. Neste trabalho, foi realizado um estudo epidemiológico transversal com método do informante para descrever doenças genéticas e as adquiridas que causam deficiências físicas em oito municípios da Paraíba e estimar os custos por serviços especializados de fisioterapia e aquisição de equipamentos de tecnologia assistiva. De uma população de 48.499 habitantes, 338 pessoas foram triadas e 123 (0,34%) realizaram avaliação clínico-genética e funcional por uma equipe multidisciplinar de especialistas. Fatores genéticos foram responsáveis por 58,5% das deficiências, sendo encontrados alguns agrupamentos de afecções prevalentes nas populações amostradas: amiotrofia espinal progressiva, ataxia espinocerebelar, distrofia muscular e síndrome Spoan. A descrição do perfil socioeconômico e das demandas por serviços de reabilitação e tecnologia assistiva apontam para necessidade de estabelecimento de políticas públicas específicas para essas comunidades.

The population of the northeast of Brazil is characterized by high rates of endogamy and disabilities. An epidemiological cross-sectional study using the informant method was conducted in eight communities in the hinterlands of Paraiba to describe genetic and acquired diseases that cause disabilities and to estimate the costs of specialized services such as physiotherapy and the acquisition of technological assistential equipment. From a population of 48,499 inhabitants, 338 individuals were screened and 123 (0.34%) were clinically, genetically and functionally assessed by a multidisciplinary team of specialists. Genetic factors were responsible for 58.5% of the disabilities, with some clusters of prevalent diseases being found within the sampled communities, namely progressive spinal muscular atrophy, spinocerebellar ataxia, muscular dystrophy and Spoan syndrome. The socioeconomic profile and the demand for rehabilitation services and technological assistance highlight the need to introduce and implement specific public health policies in these communities.